The University of Nebraska Medical Center is now part of an international hepatitis C registry that will track thousands of patients over the next five years to monitor the effectiveness and safety of new drugs. Chief of the Division of Gastroenterology and Hepatology Dr. Mark Mailliard says they will also be able to gather information on the impact of new medications that will soon be made available.
The network will track thousands of patients over the next five years to monitor the effectiveness and safety of new drugs to determine which ones are most effective and can cure the disease quickly with the fewest side effects.
103 locations in 31 states, Puerto Rico, Canada and Europe are partnering with the U-S Food and Drug Administration to form this network. Dr. Mailliard says so far they have provided outcome information on more than 120 patients of the 2,000 studied so far and the treatment success rate was significantly better than the average rate.
People born between 1945 and 1965 are encouraged to get tested since many don’t recognize they are at risk for the disease. Hepatitis C is usually spread through contact with an infected person’s blood. That population is more at risk due to past risky behavior and that includes the sharing of needles and syringes to inject drugs.
Anyone being treated for the virus using newer medications is eligible to participate in the registry.